Prospects and Potential for Chimerism Analysis after Allogeneic Hematopoietic Stem Cell Transplantation
Open Access
Abstract
Chimerism analysis after allogeneic hematopoietic stem cell transplantation serves to confirm engraftment, indicate relapse of hematologic malignancy, and attribute graft failure to either immune rejection or poor graft function. Short tandem repeat PCR (STR-PCR) is the prevailing method, followed by quantitative real-time PCR (qPCR), with detection limits of 1–5% and 0.1%, respectively. Chimerism assays using digital PCR or next-generation sequencing, both of which are more sensitive than STR-PCR, are increasingly used. Stable mixed chimerism is usually not associated with poor outcomes in non-malignant diseases, but recipient chimerism may foretell relapse of hematologic malignancies, so higher detection sensitivity may be beneficial in such cases. Thus, the need for and the type of intervention, e.g., immunosuppression regimen, donor lymphocyte infusion, and/or salvage second transplantation, should be guided by donor chimerism in the context of the feature and/or residual malignant cells of the disease to be treated.Keywords
This publication has 105 references indexed in Scilit:
- Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte InfusionsTransplantation and Cellular Therapy, 2010
- Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignanciesHaematologica, 2009
- Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAABritish Journal of Haematology, 2009
- Impact of T Cell Chimerism on Clinical Outcome in 117 Patients Who Underwent Allogeneic Stem Cell Transplantation with a Busulfan-Containing Reduced-Intensity Conditioning RegimenTransplantation and Cellular Therapy, 2008
- Clinical outcomes of late rather than early full-donor chimerism in patients with advanced lymphomas receiving nonmyeloablative allogeneic hematopoietic SCTBone Marrow Transplantation, 2008
- Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantationHaematologica, 2007
- Complete donor chimaerism of Langerhans cells in lymph node early after allogeneic bone marrow transplantationEuropean Journal of Haematology, 2006
- Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative ConditioningJournal of Clinical Oncology, 2005
- Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testingBone Marrow Transplantation, 2001
- Monitoring of lineage-specific chimaerism allows early prediction of response following donor lymphocyte infusions for relapsed chronic myeloid leukaemiaBone Marrow Transplantation, 1998